Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours

NCT01161316 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

194

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: mFOLFOX-6 + cetuximab until disease progression or early withdrawal.
DRUG: 8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.

Sponsor

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)